Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Sunitinib
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(10)
+
-
Doctoral Thesis
(5)
+
-
Availability
Open access
(4)
+
-
Some under embargo
(2)
+
-
Metadata Only
(9)
+
-
Creation Date
2015
(3)
+
-
2014
(2)
+
-
2016
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(13)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(13)
+
-
Dissertations
(5)
+
-
Topic
Sunitinib
(15)
+
-
GIST
(6)
+
-
Imatinib
(6)
+
-
Pharmacogenetics
(4)
+
-
Pharmacokinetics
(4)
+
-
Metastatic renal cell carcinoma
(3)
+
-
Tyrosine kinase inhibitor
(3)
+
-
Gastrointestinal stromal tumour
(2)
+
-
KIT
(2)
+
-
Pazopanib
(2)
+
-
Progression-free survival
(2)
+
-
Single nucleotide polymorphism
(2)
+
-
Show more
Author
Gelderblom, H.
(10)
+
-
Guchelaar, H.J.
(4)
+
-
Blay, J.Y.
(3)
+
-
Erp, N.P. van
(3)
+
-
Schoffski, P.
(3)
+
-
Wit, D. de
(3)
+
-
Bauer, S.
(2)
+
-
Castellano, D.
(2)
+
-
Demetri, G.D.
(2)
+
-
Diekstra, M.H.M.
(2)
+
-
E. boven
(2)
+
-
Garcia-Donas, J.
(2)
+
-
Hartigh, J. den
(2)
+
-
Heinrich, M.C.
(2)
+
-
Hollander, M. den
(2)
+
-
Italiano, A.
(2)
+
-
Konig-Quartel, J.M.C.
(2)
+
-
Liu, X.
(2)
+
-
Reichardt, P.
(2)
+
-
Rini, B.I.
(2)
+
-
Rodriguez-Antona, C.
(2)
+
-
Rutkowski, P.
(2)
+
-
Swen, J.J.
(2)
+
-
Show more
Language
en
(15)
+
-
Search results
(1 - 15 of 15)
show grid
show list
save search
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II tri
Pharmacogenetics and cost-effectiveness of systemic treatment in soft tissue sarcoma
Optimization of sunitinib treatment in metastatic renal cell carcinoma : pharmacogenetic evidence and challenges
Pharmacogenetics of sunitinib in metastatic renal cell carcinoma
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma
Dose optimization of oral targeted therapies in oncology
Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
Marginal increase of sunitinib exposure by grapefruit juice
Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib